SUMMIT THERAPEUTICS INC (SMMT) Fundamental Analysis & Valuation

NASDAQ:SMMT • US86627T1088

Current stock price

15.6 USD
+0.09 (+0.58%)
At close:
15.7 USD
+0.1 (+0.64%)
After Hours:

This SMMT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SMMT Profitability Analysis

1.1 Basic Checks

  • In the past year SMMT has reported negative net income.
  • SMMT had a negative operating cash flow in the past year.
  • In the past 5 years SMMT always reported negative net income.
  • In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • SMMT has a worse Return On Assets (-230.24%) than 90.37% of its industry peers.
  • SMMT has a worse Return On Equity (-287.57%) than 72.64% of its industry peers.
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SMMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SMMT Health Analysis

2.1 Basic Checks

  • SMMT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SMMT has been increased compared to 5 years ago.
  • SMMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • SMMT has an Altman-Z score of 96.93. This indicates that SMMT is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SMMT (96.93) is better than 98.65% of its industry peers.
  • There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 96.93
ROIC/WACCN/A
WACCN/A
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 5.13 indicates that SMMT has no problem at all paying its short term obligations.
  • With a Current ratio value of 5.13, SMMT perfoms like the industry average, outperforming 56.45% of the companies in the same industry.
  • A Quick Ratio of 5.13 indicates that SMMT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.13, SMMT is in line with its industry, outperforming 57.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.13
Quick Ratio 5.13
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SMMT Growth Analysis

3.1 Past

  • The earnings per share for SMMT have decreased strongly by -161.29% in the last year.
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SMMT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.80% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.53%
EPS Next 2Y-11.83%
EPS Next 3Y14.06%
EPS Next 5Y36.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SMMT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SMMT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • SMMT's earnings are expected to grow with 14.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.83%
EPS Next 3Y14.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SMMT Dividend Analysis

5.1 Amount

  • No dividends for SMMT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SMMT Fundamentals: All Metrics, Ratios and Statistics

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (3/23/2026, 8:19:14 PM)

After market: 15.7 +0.1 (+0.64%)

15.6

+0.09 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-29
Earnings (Next)04-29
Inst Owners15.51%
Inst Owner Change12.39%
Ins Owners86.05%
Ins Owner Change2.45%
Market Cap12.10B
Revenue(TTM)N/A
Net Income(TTM)-746.08M
Analysts79.13
Price Target33.08 (112.05%)
Short Float %25.73%
Short Ratio13.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.73%
Min EPS beat(2)-24.49%
Max EPS beat(2)3.04%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-24.49%
Max EPS beat(4)3.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.96%
EPS NY rev (3m)0.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 46.62
P/tB 46.99
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 475%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.13
Quick Ratio 5.13
Altman-Z 96.93
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.01%
Cap/Depr(5y)64.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
EPS Next Y-26.53%
EPS Next 2Y-11.83%
EPS Next 3Y14.06%
EPS Next 5Y36.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.2%
EBIT Next 3Y-56.36%
EBIT Next 5Y-41.47%
FCF growth 1Y-352.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-352.1%
OCF growth 3YN/A
OCF growth 5YN/A

SUMMIT THERAPEUTICS INC / SMMT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUMMIT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SMMT.


Can you provide the valuation status for SUMMIT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to SUMMIT THERAPEUTICS INC (SMMT). This can be considered as Overvalued.


Can you provide the profitability details for SUMMIT THERAPEUTICS INC?

SUMMIT THERAPEUTICS INC (SMMT) has a profitability rating of 0 / 10.


Can you provide the financial health for SMMT stock?

The financial health rating of SUMMIT THERAPEUTICS INC (SMMT) is 7 / 10.